Emerging Markets Regulatory Tracker: Australia And China
This article was originally published in PharmAsia News
Executive Summary
Australia ends a transition period for reclassification of joint replacements, while China has unveiled new drug and device manufacturing inspection rules and stricter local regulation of device clinical trials.